Source comparison
Melanotan-2 Alternatives 2026 Best: Safety Comparison
| Compound/Method | Primary Mechanism | FDA Status | Melanin Increase Timeline | Cardiovascular Risk | Melanoma Amplification Risk | Bottom Line for 2026 ||—|—|—|—|—|—|| Afamelanotide (Scenesse) | Selective MC1R agonist | FDA-approved for EPP/vitiligo | 20–30%
This comparison does not assign a generated winner or score.
- | Compound/Method | Primary Mechanism | FDA Status | Melanin Increase Timeline | Cardiovascular Risk | Melanoma Amplification Risk | Bottom Line for 2026 ||—|—|—|—|—|—|| Afamelanotide (Scenesse) | Selective MC1R agonist | FDA-approved for EPP/vitiligo | 20–30% in 4 weeks | Minimal (no MC3R/MC4R activation) | Not documented in clinical trials | Gold standard. Restricted to prescription use for approved conditions || Forskolin + UVB | Tyrosinase upregulation via cAMP | Supplement (unregulated) | 12–18% in 8–12 weeks | None documented | Proportional to UV exposure only | Slower onset, safer long-term profile || L-Tyrosine + Catalase Inhibitors | Substrate availability + enzyme activity | Supplement (unregulated) | 15–22% in 6–8 weeks | None documented | None independent of UV | Substrate-based; requires UV pairing || GHK-Cu (Copper Peptides) | Tyrosinase cofactor activation | Cosmetic ingredient (unregulated) | 10–15% in 8 weeks | None documented | None documented | Topical only; minimal